| |
Wednesday, March 26, 2025 | 2pm ET / 11am PT Understanding a molecule’s characteristics early in development helps minimize challenges and streamline the path to manufacturing. This webinar will explore key considerations in developability assessment, the role of in silico tools in molecular evaluation, and strategies for improving data security in the process.Register now to join us.
|
|
| By Zoey Becker The company revealed a plan to shutter the site back in March of 2022. Now, more than 150 staffers are set to lose their jobs throughout the rest of 2025 and into 2026. |
|
|
|
By Gabrielle Masson After serving as the director of the National Human Genome Research Institute for more than 15 years, Eric Green, M.D., Ph.D., has suddenly departed. |
By Eric Sagonowsky,Angus Liu,Fraiser Kansteiner,Andrea Park,Kevin Dunleavy,Zoey Becker Johnson & Johnson, Amgen, Regeneron, Novartis and other Big Pharma players are facing down sizable U.S. losses of exclusivity in 2025. |
By Conor Hale Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to treating people with Type 2 diabetes, placing them ahead of new medications. |
|
Thursday, March 27, 2025 | 11am ET / 8am PT This webinar will explore the growing need for process intensification in bioprocessing as a crucial step toward enhancing efficiency and sustainability.Join us to gain valuable insights into overcoming challenges related to bioprocess scale-up, including the adaptation of novel bioreactors, media formulations, and cell culture practices.Register now.
|
|
By Kevin Dunleavy Two months after U.S. President Donald Trump proclaimed DEI programs “illegal and immoral,” Roche has reportedly scrapped its high-profile five-year plan to increase the diversity of its leadership. Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, according to Reuters. |
By Fraiser Kansteiner Novartis is laying off 427 employees who report to its headquarters in East Hanover, New Jersey. The company is changing its cardiovascular commercialization model ahead of Entresto's expected loss of exclusivity this summer, a company spokesperson said. |
By James Waldron Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. |
By James Waldron AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. |
By Angus Liu One patient with Duchenne muscular dystrophy has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said Tuesday. |
By Andrea Park As the college basketball March Madness tournament tips off this week, so too does Fierce Pharma Marketing’s annual #FierceMadness competition. |
By Darren Incorvaia As fungi resistant to traditional treatments continue to spread around the globe, researchers from China Pharmaceutical University in Nanjing have identified a bacterial compound that can kill infectious fungi even if they’re resistant to other antifungals. |
Fierce podcastsDon’t miss an episode |
| | Executive Editor Heather Landi and Senior Writer Paige Minemyer sit down to chat about the evolution of the Fierce 15 project and honorees. |
|
|---|
|
|
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing.Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
